Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech’s First Quarter Solid, Avastin Slow

This article was originally published in The Pink Sheet Daily

Executive Summary

Breast-cancer push not yet in full swing, company says.

You may also be interested in...



Rituxan For Lupus Misses Primary, Secondary Endpoints

Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.

Rituxan For Lupus Misses Primary, Secondary Endpoints

Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.

Avastin Misses Overall-survival Endpoint In Lung Cancer

Analysts expect minimal damage to sales as a result of AVAiL data.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel